Guardion Health Sciences, Inc. (GHSI): Price and Financial Metrics
GHSI Price/Volume Stats
| Current price | $7.95 | 52-week high | $10.50 |
| Prev. close | $7.64 | 52-week low | $4.66 |
| Day low | $7.68 | Volume | 3,100 |
| Day high | $8.00 | Avg. volume | 16,091 |
| 50-day MA | $7.70 | Dividend yield | N/A |
| 200-day MA | $6.96 | Market Cap | 10.12M |
GHSI Stock Price Chart Interactive Chart >
GHSI Stock Summary
- GUARDION HEALTH SCIENCES INC's market capitalization of $10,186,368 is ahead of only 5.91% of US-listed equities.
- The ratio of debt to operating expenses for GUARDION HEALTH SCIENCES INC is higher than it is for about merely 0.33% of US stocks.
- With a year-over-year growth in debt of -100%, GUARDION HEALTH SCIENCES INC's debt growth rate surpasses merely 0% of about US stocks.
- Stocks that are quantitatively similar to GHSI, based on their financial statements, market capitalization, and price volatility, are CBRL, AAN, HLF, PATI, and UNM.
- Visit GHSI's SEC page to see the company's official filings. To visit the company's web site, go to www.guardionhealth.com.
GHSI Valuation Summary
- GHSI's EV/EBIT ratio is -0.2; this is 101.61% lower than that of the median Healthcare stock.
- Over the past 54 months, GHSI's EV/EBIT ratio has gone up 9.5.
Below are key valuation metrics over time for GHSI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| GHSI | 2023-09-18 | 0.9 | 1.4 | -0.8 | -0.2 |
| GHSI | 2023-09-15 | 0.9 | 1.4 | -0.8 | -0.2 |
| GHSI | 2023-09-14 | 0.9 | 1.4 | -0.8 | -0.1 |
| GHSI | 2023-09-13 | 0.9 | 1.4 | -0.8 | -0.1 |
| GHSI | 2023-09-12 | 0.9 | 1.4 | -0.8 | -0.1 |
| GHSI | 2023-09-11 | 0.8 | 1.3 | -0.8 | -0.1 |
GHSI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GHSI has a Quality Grade of D, ranking ahead of 6.18% of graded US stocks.
- GHSI's asset turnover comes in at 0.071 -- ranking 291st of 677 Pharmaceutical Products stocks.
- PBH, TXMD, and NVS are the stocks whose asset turnover ratios are most correlated with GHSI.
The table below shows GHSI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.071 | -0.042 | -3.780 |
| 2021-03-31 | 0.093 | -0.050 | -7.284 |
| 2020-12-31 | 0.147 | -0.030 | -5.816 |
| 2020-09-30 | 0.142 | 0.509 | -5.190 |
| 2020-06-30 | 0.144 | 0.507 | -5.304 |
| 2020-03-31 | 0.085 | 0.606 | -6.883 |
Guardion Health Sciences, Inc. (GHSI) Company Bio
Guardion Health Sciences, Inc. provides health care services. It offers, Lumega-Z a medical food formulated to replenish and restore the macular protective pigment. The firm also develops medical devices that measures macular pigment density. The company was founded by Michael Favish in 2009 and is headquartered in San Diego, CA.
Latest GHSI News From Around the Web
Below are the latest news stories about GUARDION HEALTH SCIENCES INC that investors may wish to consider to help them evaluate GHSI as an investment opportunity.
Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023Viactiv® Product Line Total Revenue Increased Approximately 6% for the Six Months Ended June 30, 2023, as Compared to the Six Months Ended June 30, 2022; Robust Growth in Amazon Sales Channel Demonstrates Positive Results of Company’s Focus on eCommerce InitiativesHOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to su |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday! |
Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall as President and Chief Executive OfficerFormer President and Chief Executive Officer Bret Scholtes Resigning to Pursue Other Business OpportunitiesHOUSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that Janet (“Jan”) Hall has been appointed as the Com |
Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023Viactiv® Product Line Total Revenue Increased approximately 37% for the Quarter Ended March 31, 2023 as compared to the Quarter Ended March 31, 2022HOUSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financia |
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022Viactiv® Product Line Generated Net Revenues of approximately $10.6 Million or 96% of Net Revenues for the Year Ended December 31, 2022HOUSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results f |
GHSI Price Returns
| 1-mo | 4.94% |
| 3-mo | 15.80% |
| 6-mo | 53.77% |
| 1-year | 17.60% |
| 3-year | -88.54% |
| 5-year | N/A |
| YTD | 9.58% |
| 2022 | -77.58% |
| 2021 | -74.01% |
| 2020 | 88.38% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...